| Quantity: | |
|---|---|
Clinically Relevant – Overview of human autoimmune uveitis with Th1/Th17-mediated inflammation, retinal damage, and blood-retinal barrier disruption.
Advanced imaging endpoints – fundus photography and scoring, optical coherence tomography (OCT) for retinal thickness measurement.
Comprehensive pathology – Histopathology (HE staining) of inflammatory infiltrate and retinal structural damage.
Mechanistically driven – IRBP activates antigen-presenting cells, driving Th1 and Th17 differentiation and the production of inflammatory cytokines (IFN-γ, IL-17, TNF-α).
IND Ready Packet – Research can be conducted in accordance with GLP principles.
IRBP Inducible C57BL/6 EAU model
• Testing the efficacy of immunomodulators (corticosteroids, methotrexate, mycophenolate mofetil) in the treatment of autoimmune uveitis
• Evaluate biologics targeting the Th1/Th17 pathway (anti-IL-17, anti-IL-23, anti-IFN-γ)
• Target validation of ocular T cell-mediated autoimmune responses
• Biomarker discovery (inflammatory cytokines, retinal damage markers)
• Pharmacology and toxicology studies to support IND
scope | Specification |
Species/Strain | C57BL/6 mouse |
induction method | Immunize subcutaneously with IRBP peptides emulsified in CFA (e.g., IRBP1-20, 200-300 μg), supplemented with Mycobacterium tuberculosis, and plus intraperitoneal pertussis toxin (0.5-1 μg) at the time of immunization |
study time | 21–35 days after immunization (peak of disease ~14–21 days) |
critical endpoint | Fundus photography and clinical scoring (grade 0-4 of optic disc, vasculitis, infiltrates), optical coherence tomography (OCT) for retinal thickness measurement, OCT score, histopathology (retinal HE staining to detect inflammatory infiltrate and structural damage), optional: flow cytometry of retinal/lymph node immune cells (CD4+ T cells, Th1/Th17 subsets), cytokine analysis (IFN-γ, IL-17, tumor necrosis factor-α) |
packet | Raw data, analysis reports, fundus images, OCT data, histological sections, bioinformatics (optional) Raw data, analysis reports, clinical scores, histological sections, serum analysis (IL-6, CRP), optional: anti-CII antibodies, micro-CT imaging |
Q: How does IRBP induce EAU?
Answer: IRBP is a retinal antigen. Immunization with IRBP peptides in adjuvants activates antigen-presenting cells, which present antigen to naive T cells, driving their differentiation into pathogenic Th1 and Th17 effector cells. These cells infiltrate the eye, release inflammatory cytokines (IFN-γ, IL-17, TNF-α), and cause retinal inflammation and damage.
Q: What are the key similarities to human autoimmune uveitis?
A: This model exhibits T cell-mediated inflammation (Th1/Th17), blood-retinal barrier disruption, inflammatory cell infiltration, retinal structural damage, and clinical signs visible on funduscope and OCT, which are closely related to human non-infectious uveitis.
Q: Can this model be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different IRBP peptides, doses, treatment times)?
Answer: Of course. Our scientific team tailors immunization regimens, treatment plans and endpoint analyzes to your specific drug candidate.
